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Abstract 
The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream 
opened up new avenues towards noninvasive prenatal testing (NIPT) for aneuploidies, 
hereditary DNA mutations and other pregnancy-related developmental disorders. 
Increasingly, cfDNA catches interest for its noninvasive screening value in other areas 
as well, including oncology. Although there are indications that cfDNA fragmentation 
is a non-random process, the etiology and different structural aspects of cfDNA are 
still not well known. The emerging field of cfDNA fragmentomics investigates the 
existence of tissue and disease specific cfDNA signatures and the chemistry and 
biology underlying the fragmentation process. This review sheds light on recent 
developments in cfDNA fragmentomics and illustrates their significance in NIPT 
improvement and beyond. 
We discuss aspects of fragment size distributions, epigenetic correlations and 
putatively enriched cfDNA fragment-end compositions. Combinatorial fragmentomic 
efforts have provided more insights into the roles of different enzymes that contribute 
to the fragmentation process in the tissue of origin and in the bloodstream. Altogether, 
these studies revealed multiple fragmentomic-related biomarkers that can be used to 
make noninvasive screening and other types of clinical use of cfDNA more robust, by 
raising its distinctive capacities. This includes multiple complementary approaches to 
determine the fetal fraction, a key determinant in NIPT. Furthermore, these 
developments translate to a better understanding of the encountered cfDNA patterns 
and will catalyze the expansion of screening possibilities in NIPT and beyond.  
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INTRODUCTION 
 Invasive prenatal testing methods such as 
amniocentesis and chorionic villus sampling (CVS) pose 
iatrogenic risks for both mother and fetus.1 This problem 
could be overcome by using safer methods based on 
maternal blood sampling in prenatal screening. The 
presence of intact nucleated cells of fetal origin in the 
bloodstream of pregnant women was first reported in 
18932, and later prompted speculation of their clinical 
significance and potential applications in noninvasive 
prenatal testing (NIPT).3 Although the existence of 
double-stranded cell-free DNA (cfDNA) in blood was 
first demonstrated in 19484, qualitative evidence for 
presence of cell-free fetoplacental DNA (cffDNA) traces 
among the cfDNA pool of the carrying mother was not 
found until 1997.5 Parallel advancements in nucleic acid 
analysis methods consequently promoted development of 
strategies for quantification of cffDNA from maternal 
blood samples as an alternative approach to perform 
prenatal genome screening.6 The first successful 
demonstrations of cffDNA-based screening advocated 
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the improved patient safety, operational ease, time 
efficiency and scalability as compared to invasive 
methods.7-9  
 In the subsequent decade, fast-paced concurrent 
developments in sophisticated sequencing technology 
further enabled increasingly accurate restoration of the 
fetal genome from maternal plasma, even reaching the 
point of full recovery of the entire fetal genome.10 
 The levels of cffDNA in pregnant women are 
dynamic during the entire pregnancy, reaching highest 
levels near delivery.11 Delivery is succeeded by rapid 
biphasic clearance from the maternal plasma, with 
estimated cffDNA half-lives of 1 hour and 13 hours 
respectively, rendering it undetectable typically within 
two days postpartum.12 Increased levels of cffDNA have 
been correlated to fetal aneuploidy8,13 but also to 
pregnancy anomalies including pre-eclampsia14,15, 
hyperemesis gravidarum16 and premature labor.17 
However, increased cfDNA levels alone have limited 
diagnostic value at the individual patient level. Initial 
cfDNA-based screening offered opportunities to 
perform fetal sex determination, identify paternally 
inherited traits and detect fetal aneuploidies.7,9,18 The 
major breakthrough came in 2008 with the first 
description of exploring cffDNA with next-generation 
sequencing, allowing for noninvasive detection of fetal 
trisomies by increased levels of cfDNA originating from 
chromosomes 13, 18 or 21 in maternal blood.19,20 
Noninvasive restoration of the entire fetal genome10 was 
followed by genome-wide noninvasive aneuploidy 
detection18 and noninvasive aneuploidy detection in 
multiple pregnancies.21-23 The discovered potential of 
cfDNA as an alternative, reliable and noninvasive 
diagnostic source led to rapid clinical implementation as 
a second (after combined testing) or first-tier test in 




Figure 1. Timeline of the main events leading towards the 
development of NIPT 
 
 Analogously to the successive developments 
preceding clinical NIPT integration, the detection of 
tumor-derived cfDNA, referred to as circulating tumor 
DNA (ctDNA), was pivotal in the development of 
noninvasive cancer detection methods, also known as 
liquid biopsies.30 The fields of oncology and prenatal 
screening and diagnostics perpetually exchange 
developments, and sometimes even intersect when 
ctDNA is detected during NIPT.29,31 Also in cardiology 
and neurogenetics, liquid biopsies have been shown 
useful for clinical monitoring, for instance for heart 
failure32 and neuronal atrophy.33 Somewhat less known, 
but not less promising, are the pioneering efforts in 
cfDNA-based organ transplants monitoring34,35 and 
cfDNA-based diagnostics of parasitic36, viral37 or 
bacterial38 infections. Moreover, other medical 
disciplines have reported presence of cfDNA in body 
fluids other than blood plasma, including urine and 
saliva, which in turn provides stimulus and opportunities 
for further expansion of noninvasive medical research.  
 Despite its widespread use in clinical practice, most 
molecular features of cfDNA itself remained poorly 
studied for a long period and much of the underlying 
biology remains to be resolved. Recent attempts to 
elucidate other cfDNA characteristics have consistently 
demonstrated reproducible cell-type specific patterns in 
fragment size distributions, genomic origin and other 
features such as methylation profiles. These consistent 
observations indicated that cfDNA fragmentation is a 
non-random process, which sparked impulse in the 
emerging field of ‘cfDNA fragmentomics’. Deciphering 
the architecture and etiology of cfDNA landscapes may 
lead to better understanding of the involved biological 
processes and could provide novel insights for improving 
diagnostics and screening including, but not limited to, 
NIPT. This review sheds light on the recent 
developments in the field of cfDNA fragmentomics and 
aims to illustrate their significance for NIPT. 
 
FRAGMENT SIZE DISTRIBUTION PATTERNS 
 Early observations of increased cfDNA levels in 
cancer patients raised questions regarding the tissue of 
origin of the excess cfDNA.39 Tumor-specific altered 
methylation patterns allowed Jahr and colleagues to 
discriminate between ctDNA and non-ctDNA pools, and 
to determine the tumor-derived fraction in patient 
samples.40 The same authors demonstrated a correlation 
between the presence of apoptotic or necrotic tissue and 
increased overall cfDNA levels, supporting the concept 
that tumors likely contribute to elevated cfDNA levels. 
Their results suggested necrotic cells dispose of large 
DNA fragments (>10,000 bp) whereas apoptotic tissue 
produced smaller fragment sizes of approximately 180 
bp, and multiples thereof, reminiscent of earlier reported 
nucleosomal fragmentation patterns found in apoptotic 
cells.41 cfDNA size features continued to be studied 
hereafter, with use of electrophoresis techniques, 




Figure 2. Schematic overview of the ‘beads-on-a-string’ 
architecture of nuclear DNA. ~146 bp DNA winds around a 
core histone octamer to yield a nucleosome core unit. When the 
linker histone H1 binds to this complex, an additional ~10 bp 
on both DNA ends are bound, yielding a chromatosomal unit 
encompassing ~166 bp in total. These units are interspaced by 
linker DNA of arbitrary length. Intermediate condensed 
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 In pregnant women, it was found that the size 
distribution of cffDNA shifts to be slightly shorter on 
average than that of cfDNA fragments originating from 
maternal tissue.43 A paired-end sequencing study by Lo 
and colleagues in 2010 aided in the accurate 
determination of cfDNA size distributions, revealing a 
major ~166 bp peak, a less pronounced ~143 bp peak and 
recurrent 10 bp-interspaced declining peaks for cfDNA 
from pregnant women, which is composed of both 
maternal- and fetal-derived fractions. In the fetal derived 
cfDNA, the difference between the 166 bp and 143 bp 
peak was smaller compared to the difference seen for the 
maternally derived fragments, confirming that the fetal 
fraction is enriched for the shorter (~143 bp) 
fragments.10 As with DNA from apoptotic tumor tissue, 
these fragment sizes are reminiscent of the nucleosomal 
‘beads-on-a-string’ organization of nuclear DNA, since 
they reflect the dimensions and periodicity of histone-
wound sequences44 (Figure 2). 
 This remarkable shift in size distribution instigated 
approaches to discriminate fetal from maternal cfDNA 
from the combined pool present in maternal plasma. 
Especially in early gestation, a low fetal fraction and 
high background maternal signal pose a major hurdle for 
the sensitivity of NIPT.45 The discovery of distinct size 
distributions prompted the concept that low-abundance 
cffDNA could be enriched for by size selection. This led 
to multiple novel size-based approaches to effectively 
increase the detected fetal fraction.46-51 Yet, while 
increasing the detected fetal fraction, this type of 
enrichment was also shown to reduce the total count of 
cffDNA molecules detected, counterproductively 
impacting the statistical significance of any aberrations 
of interest detected.52 Instead, by applying size-based 
discrimination in silico, size distribution shifts were 
found to be of diagnostic purpose in sex-independent 
fetal fraction determination53, identification of aneuploid 
pregnancies54 and distinguishing fetal aberrations from 
maternal ones.55 Especially in aneuploidy detection, both 
size distribution shifts and read counts of potentially 
aneuploid fetal chromosomes can function cooperatively 
to achieve supplemented and accurate results. Similarly, 
ctDNA fragment size as fragmentomic marker has 
shown to be of value for enhanced noninvasive detection 
of cancers.56 
 
EPIGENETIC PATTERNS IN 
FRAGMENTOMICS 
 The first concrete evidence linking the size 
distribution of cfDNA to the nucleosomal organization 
was found in 2008 by using paired-end sequencing to 
demonstrate that the ends of cfDNA fragments map to 
genomic chromatin regions covered by nucleosomes, 
such as regions surrounding transcribed genes.20 The 
authors emphasized consistent periodic alignment of 
cfDNA fragments just downstream of transcriptional 
start sites, which is in line with characterized eukaryotic 
histone occupancy at such genomic loci.57 This relation 
between nucleosome positions and distribution and 
length of cfDNA has been confirmed with different 
approaches by several independent groups, even 
allowing the determination of genome wide nucleosome 
pattern based on starting positions of sequence 
reads.53,58,59 Moreover, it was found that cfDNA 
originating from mitochondria and viruses are 
abundantly enriched for smaller sized (<50bp) fragments 
which explicitly do not obey the periodic distribution 
patterns as found for cfDNA of nuclear origin.10,58 Given 
that the mitochondrial and viral genomes use alternative, 
non-nucleosomal, DNA packaging mechanisms60, these 
findings support the theory that nuclear-derived cfDNA 
fragmentation is not a random process and might be 
associated with detailed aspects of nucleosomal 
organization. 
 Nucleosomal occupancy is strongly associated with 
the transcriptional activity of specific genomic 
regions.61,62 Methylation of cytosine residues at the DNA 
level has been shown to moderate a nucleosome’s 
positioning and its regulatory effects.63,64 Studies on 
tissue-specific differential methylation of genomic 
regions, and especially dysregulation thereof, contributed 
to profound understandings in cancer research.65 The 
discovery that epigenetic nucleic acid modifications, 
rather than the actual DNA sequence itself, could be used 
for discriminating cfDNA originating from different 
tissues caused interest in the development of tissue-
specific diagnostic and therapeutic strategies.  
 For the NIPT field, this logically translated into 
attempts to discriminate cffDNA from a maternal cfDNA 
pool, based on fetoplacental tissue-specific hyper-
methylated genomic regions. The SERPINB5 locus on 
chromosome 18 was the first of such regions on which 
this principle was demonstrated to determine fetal 
trisomy 18.66 A decade later, this extrapolated to 
methylotyping over 5,000 regions in parallel, 
simultaneously distinguishing cfDNA from a range of 
tissues including the placenta.67 Major advantages over 
conventional methods include that the procedure does not 
require knowledge on parental haplotypes nor on fetal 
sex. However, distinguishing hypo-methylated fetal 
DNA typically involves toxic bisulfite treatment which 
extends the laboratory workflow and notably is known to 
degrade more than 90% of the DNA present in a 
reaction.68 For NIPT in particular, this is a major 
drawback, as the fetal fractions studied already are very 
low. Methylation-sensitive enzymatic restriction, as a 
cheaper alternative method, is mainly limited in terms of 
which sequences can be targeted. Methylated DNA 
immunoprecipitation offers a relatively flexible and 
sensitive approach, but involves more costly tailored 
antibodies. A combination of these strategies has recently 
allowed for a methylation-based estimation of the fetal 
fraction.69 
 Methylation-sensitive digestion of the cfDNA pool, 
in which methylated nucleotides are protected from 
degradation, depletes abundant hypo-methylated 
maternal sequences, allowing to increase the fraction of 
cffDNA. Hyper-methylated fetoplacental genomic loci, 
such as RASSF1A, SOX14 and TBX3, may serve as useful 
marker candidates in such enrichment approaches.70,71 
Further exploration of the fetoplacental methylome 
showed that, overall, it is initially hypo-methylated, but 
dynamically changes with gestational age.72 This 
suggests that the most pronounced maternal-fetal 
methylome differences occur within the first trimester, 
when most NIPT analysis are performed, as compared to 
the third trimester, in which cffDNA was found to be 
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conventional genetic markers, this highlights that 
reversibility and fluctuation of epigenetic markers need 
to be taken into account when setting up assays. 
Dysregulation of the normally tightly regulated placental 
epigenome is associated with impaired fetal 
development and placental dysmorphology, prompting 
recent efforts to demonstrate methylotyping of cffDNA 
could also serve an inherent diagnostic purpose, rather 
than solely providing complementary approach for fetal 
fraction determination.73 
 Apart from DNA-methylation, a myriad of histone 
modifications has been characterized that mediate 
nucleosomal positioning.74 By maintaining a tailored 
nucleosomal organization, these factors constitute a 
tissue-specific epigenetic transcription control. As a 
consequence, nucleosomal organizations retain 
genotype-independent information on the corresponding 
tissue of origin. Deep sequencing of cfDNA pools has 
been shown to yield alternate coverages around tissue-
specific genes compared to housekeeping genes, indeed 
suggesting that cfDNA mapping can be used to trace 
back the nucleosomal landscape architecture and thereby 
link it to the tissue of origin.75 Whereas in healthy 
individuals the majority of the cfDNA pool is of 
hematopoietic origin, cfDNA pools of different types of 
cancer patients reflect increased contributions coming 
from corresponding tumor tissues.59 A differential 
tissue-specific histone architecture is expected to result 
in a shift of mapped cfDNA fragment ends, as histone 
depleted regions are expected to be degraded, and vice 
versa. Bioinformatic analysis of such cfDNA 
fragmentation patterns enabled researchers to determine 
which tissues largely contributed to the cfDNA pool.76,77 
 These results suggest that in cfDNA research, 
nucleosomal profiling offers alternative approaches for 
distinguishing genetic material based on the tissue of 
origin. This was quickly demonstrated to be useful for the 
detection and monitoring of several types of cancer.59,76,77  
 For NIPT, adequate characterization of fetoplacental-
derived sequences can serve as a complementary strategy 
to determine the fetal fraction with improved accuracy, 
but it enables more than just that. Knowledge on the 
tissue of origin offers possibilities, for instance, to 
distinguish between fetuses in multiple pregnancies or to 
distinguish between fetal anomalies and maternal mosaic 
anomalies if for instance a trisomy 8 is found.78 Similarly, 
noninvasive detection of epigenetic markers on ctDNA 
allows for tracing back the tissue where the tumor is 
located.79 At the intersection of perinatal medicine and 
oncology, NIPT results sometimes display maternal 
cancer signatures29, which can be linked to a potential 





Table 1. Overview of characterized fragmentomic markers suitable for distinguishing between maternal and fetoplacental 
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cfDNA FRAGMENT END PATTERNS 
 The fact that cffDNA fragments are generally shorter 
than maternal cfDNA fragments prompted to study 
differences in genomic preferred end-sequences between 
maternal and fetoplacental cfDNA. Ultra-deep cfDNA 
sequencing of these fragment ends led to the 
characterization of fetal-specific preferred genomic 
sites.80 The same study demonstrated the use of the 
identified preferred fragment ends for determination of 
the fetal fraction. An even more accurate estimation of 
fetal fraction could be calculated by combining 
information on both fragment size and preferred 
fragment ends.81 The authors showed that such a 
combinatorial approach can increase the reliability of 
noninvasive prenatal trisomy 21 detection by enrichment 
for fetal fragments. 
 As briefly discussed above, fetal fragments are 
somewhat shorter than maternal fragments. The shorter 
fetal fragments are too short to fully wrap around a 
histone octamer twice, in contrast to maternal fragments 
which typically measure ~166bp, the length needed to 
span a complete nucleosome, including H1 (Figure 2). 
This difference is reflected by the breakpoints of both 
fetal and maternal cfDNA. Breakpoints of long (170-250 
bp) fragments map to linker DNAs that interspace 
nucleosomal sequences, whereas ends of short (60-155 
bp) fragments map to the border and central regions of 
nucleosomal DNA. This confirms that fragmentation of 
fetoplacental DNA frequently occurs at histone-bound 
sequences, whereas maternal DNA is mostly cleaved at 
the linker DNA sequences in between histones. Further 
proof was obtained by determining chromatin-
accessibility using a transposase, which makes cuts in 
non-nucleosomal DNA. Such transposase treatment 
resulted in cleavage of nucleosomal fetoplacental DNA, 
but not of nucleosomal maternal DNA.81,82 This suggests 
that fetoplacental DNA is less tightly packed around 
histones, resulting in increased accessibility for putative 
enzymes involved in fragmentation during apoptosis, 
which leads to shorter fragments as compared to 
maternal DNA fragmentation.  
 Researchers reasoned that if cfDNA fragmentation is 
indeed non-random, and there are genomic cleavage 
hotspots depending on the tissue of origin, the 
fragmentation process would lead to so-called cfDNA 
‘preferred ends’. In 2015, significantly elevated 
cytosine-rich fragment ends were found in cfDNA as 
compared to the random distribution in sonicated 
genomic DNA.58 This preference for C-rich nucleotide 
fragment end motifs has been confirmed by other 
researchers as well.83-85 Notably, this pattern was 
explicitly not observed for mitochondrial-derived 
cfDNA fragments, again supporting the view that the 
mitochondrial genome is degraded by a distinct 
mechanism.58 
 When initially examining the fragment end 
nucleotide signatures in samples from pregnant women 
through deep sequencing, insignificant differences were 
observed between fetal and maternal end patterns, 
suggesting that the same enzymatic fragmentation 
mechanism is active in both maternal and fetoplacental 
tissue.58 Five years later, the discovery that the vast 
majority of cfDNA fragment ends are staggered, instead 
of blunt, suggested that relying on deep sequencing only, 
may miss out on additional information about fragment 
end patterns.86 Fragment end restoration prior to 
sequencing revealed that different tissue types, amongst 
which the placenta, bear their own preferred fragment 
end identity. The study characterized such preferred 
tetranucleotide sequences and demonstrated their 
potential value as fragmentomic marker for cancer 
detecting cancers, monitoring organ transplants and 
prenatal testing.87 
 
DECIPHERING THE FRAGMENTATION 
MECHANISM 
 The above-mentioned organized consistencies found 
in cfDNA size distributions, related epigenetic patterns 
and fragment end compositions all support the upcoming 
paradigm that cfDNA fragmentation during apoptosis is 
a non-random process. The non-random fragmentation 
patterns have resulted in characterization of multiple 
fragmentomic markers that can aid or complement the 
NIPT diagnostic pipeline (Table 1). Proper 
understanding of the underlying fragmentation 
mechanism may lead to explanations for why maternal 
and fetal fragmentomic patterns deviate from each other, 
and could improve the use and evaluation of the derived 
fragmentomic markers in NIPT, and in other fields that 
intersect with cfDNA research.    
 In particular the observed size- and sequence-based 
preferences for fragmentation suggest that the 
mechanism involves DNA endonucleases that preferably 
cleave genomic DNA into nucleosomal fragments with 
C-rich ends. As DNase1 is one of the most prominent and 
widespread desoxyribonucleases found in mammals88, it 
was a straightforward candidate for further studies 
regarding its role in cfDNA fragmentation. However, 
since DNase1 preferentially cleaves ‘naked’ DNA 
instead of protein-bound DNA89, DNase1-deficient 
murine models did not result in significantly deviating 
cfDNA patterns, suggesting that other nucleases are more 
dominantly involved.90 
 The DNASE1L3 gene codes for DNase γ, another 
major mammalian endonuclease found in blood plasma. 
cfDNA analysis of murine models with a deficiency for 
this enzyme revealed increased levels of large 
multinucleosomal fragments as well as almost halved 
frequencies of the normally C-rich end motifs.83 Similar 
deviant cfDNA fragment size and end motif profiles have 
been found in plasma of human subjects with DNase γ-
deficiency.84 The same trend was observed in plasma of 
hepatic cancer patients, where the DNASE1L3-
expression was around 10-fold lower than in surrounding 
healthy liver tissue.87 Surprisingly, the DNase γ-deficient 
mouse models also showed an increase in shorter 
fragments (20-120bp), which was attributed to the 
autoimmune response phenotype affiliated with this 
deficiency, resulting in anti-DNA antibodies that 
presumably lead to increased fragment degradation.83 
This was verified in double-deficient mice for DNase γ 
and CD40 ligand, which were incapable to mount such 
an immune response and showed normal levels of short 
fragments. Functional DNase γ originating from the fetus 
could partially rescue the aberrant patterns of cfDNA 
originating from the DNase γ-deficient murine mother, 
implying that the protein can enter the maternal 
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systemically. Moreover, viral transfection of a DNase γ-
deficient mouse with a functional copy of Dnase1l3, the 
mouse homologue, resulted in an in vivo rescue of the 
aberrant profiles.84 The same study demonstrated in vitro 
that the DNase γ, unlike DNase1, prefers protein-bound 
DNA substrates over naked DNA substrates to generate 
fragment sizes reminiscent of a nucleosome. 
Furthermore, DNase γ has a strong preference for 
cleaving at 2 subsequent cytosines, irrespective of the 
organization of the DNA (i.e. histone-bound or naked). 
These data strongly support the major role DNase γ plays 
in cfDNA fragmentation. 
 
 Since DNase γ is secreted and continues to cleave 
DNA in the blood stream, researchers set out to 
investigate properties of ‘freshly’ released cfDNA, in 
order to investigate whether there are cellular nucleases 
involved in DNA fragmentation before cfDNA is 
released into the bloodstream. By simulating apoptotic 
conditions in in vitro cell models, Han and colleagues 
succeeded in extracting and analyzing cfDNA directly 
after excretion.85 End motifs of newly released 
fragments turned out to be relatively A-rich, suggesting 
another non-random cleavage process preceding the 
DNase γ-mediated C-rich motif end generation. The 
authors continued to show that cells deficient for the 
major apoptotic endonuclease, DNase Fragmentation 
Factor subunit Beta (DFFB), also known as caspase-
activated DNase, resulted in virtually no difference 
between end motifs of newly released cfDNA and 
cfDNA fragments that already circulated in the 
bloodstream. Similarly, they showed that the A-rich 
motifs are accumulated in cfDNA pools from DNase γ-
deficient mice, suggesting that the reaction product of 
DFFB is the substrate for DNase γ. 
 Even though C-rich ends are the most prevalent 
among the studied cfDNA ends, it was observed in wild-
type murine plasma that smaller (<150 bp) fragments 
have a slightly increased likelihood of bearing thymine-
end motifs.85 In vitro disruption of the nucleosomal 
organization by disruptive agents led to even more 
pronounced T-rich motifs, whereas DNase1-deficient 
mice did not present this preference. Given that DNase1 
prefers naked DNA as substrate, it was hence suggested 
to act as one of the last in the fragmentation process, 
preferably releasing cfDNA fragments with T-rich ends. 
Furthermore, the disruption of nucleosomes also 
eliminated the 10 bp periodicity normally found for 
fragments under 150 bp. This periodic fragment 
degradation is suggested to be resultant of a balance 
between histon-protected intranucleosomal DNA and 
degradation of exposed DNA ends, in which both strands 
are alternately exposed due to the inherent helical 10 bp-
per-turn structure. Altogether, these findings led to the 
first model for enzymatic cfDNA fragmentation as a 
biphasic process occurring during apoptosis and in the 
bloodstream85 (Figure 3). 
 
CONCLUSION 
 Cell-free nucleic acids increasingly catch interest for 
their high diagnostic value, in combination with a 
minimally invasive clinical procedure. Nevertheless, the 
underlying chemistry and biology of DNA fragmentation 
in apoptotic cells is still to be understood fully. Numerous 
patterns demonstrate the non-randomness of the cfDNA 
fragmentation process and hint for underlying 
mechanisms to be characterized. These patterns include 
fragment size distributions, epigenetic correlations and 
fragment end compositions. The upcoming field of 
cfDNA fragmentomics examines such patterns to explore 
new routes towards tracking down the underlying biology 
of cfDNA fragmentation. Similarly, other cell-free 
nucleic acids including mitochondrial-derived cfDNA 
and cfRNA are thoroughly being explored.91 A close 
understanding of the responsible fragmentation 
mechanisms involved enables developments of using 
cfDNA as a biomarker for more accurate, perhaps more 
personalized, diagnostics and screening, monitoring and 
therapeutics. 
 Rapid technological advancements have enabled 
scientists involved in cfDNA fragmentomics to study the 
link between disturbed patterns and clinical features. So 
far, cancer- and pregnancy-related research has the 
closest ties with the field of cfDNA, but other disciplines 
increasingly show efforts to study cell-free nucleic acids 
as well. Integrating cfDNA fragmentomic information 
has already been shown to improve testing sensitivity in 
noninvasive cancer diagnostics and screening.92,93 One of 
the major hurdles in prenatal screening is the accurate 
determination of the fetal fraction. This review has 
touched upon several identified fragmentomic markers 
that can be used to approach the fetal fraction, or more 
generally, to determine the maternal or fetal origin of 
variants observed using NIPT. Mostly, these are based on 
patterns that are essentially different between mother and 
fetus, allowing for distinguishing them in silico. The 
combined outcome of the most recent findings on the 
involved nuclease biology mark a point in cfDNA 
research where the fragmentation process is modelled 
and assigned to several effector nucleases. This model 
may form the base to further explore the underlying 
fragmentomic mechanisms that cause maternal and fetal 




Figure 3. Schematic overview of the cfDNA fragmentation 
model. During apoptosis, DFFB, DNase γ, and most likely a 
set of other nucleases, break down the genomic DNA into 
multinucleosomal fragments. Once released into the 
bloodstream, they are further degraded systemically by 
extracellular DNase γ to mononucleosomal units with C-rich 
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